←
Schmahmann Lab921 posts
Schmahmann Lab avatar

Schmahmann Lab

@SchmahmannLab

Jeremy D. Schmahmann, MD Massachusetts General Hospital Ataxia Center & Lab for Neuroanatomy and Cerebellar Neurobiology - Supported by the MINDlink Foundation

◷ Joined November 2009▧ 285 Photos and videos
Schmahmann Lab avatar
Schmahmann Lab@SchmahmannLab·Aug 27

Working with the Posterior Fossa Society Scoring group. What is PFS vs CCAS? Where does one leave off and the other commence? Is it PFS is when CCAS is accompanied by mutism? Terminology must reflect neuroscience and be clinically meaningful. Stay tuned.

Post attachment
Schmahmann Lab avatar
Schmahmann Lab@SchmahmannLab·Jul 13

Great on-line turnout today at the International Parkinson and Movement Disorder Society, European Section course on the Diagnosis and Treatment of Cerebellar Ataxias. Congratulations to the organizers on an excellent course.

Post attachmentPost attachmentPost attachment
Schmahmann Lab avatar
Schmahmann Lab@SchmahmannLab·May 10

With Brad @DickersonLabMGH and @MGHPsychiatry Department celebrating Dr. Janet Sherman, stepping down from directorship of the Psychology Assessment Center which she led superbly for > 35 years, one of the premier clinical, research, training programs in neuropsychology in the US

Post attachment
Schmahmann Lab avatar
Schmahmann Lab@SchmahmannLab·Apr 23

Kudos to my former postdoc Catherine Stoodley @LabStoodley for a masterful keynote address on cerebellar circuits and cognition at the Posterior Fossa Society meeting in Copenhagen today.

Post attachmentPost attachment
Schmahmann Lab avatar
Schmahmann Lab@SchmahmannLab·Mar 11

More: biospace.com/fda/opinion-rar… @SenRonJohnson @SenRickScott @SenGillibrand @NAF_Ataxia @Friedreichsatax

aging.senate.gov/hearings/fr… See the testimony before Senate on Feb 26th. Grateful to the Senators for their bipartisan commitment to FDA oversight, to bring safe and effective treatments to Americans with rare diseases. The ⁦@US_FDA⁩ needs CPR.

Post attachmentPost attachment
Schmahmann Lab avatar
Schmahmann Lab@SchmahmannLab·Mar 11

Anna Burt presenting her poster to colleagues at ⁦@anpadirect⁩ annual meeting in Providence RI on the cerebellar neuropsychiatric rating scale version 2. Another great ANPA meeting with superb science and wonderful networking in Neuropsychiatry / Behavioral Neurology ⁦

Post attachment
Movement Disorders Clinical Practice avatar
⟳ Schmahmann Lab retweeted
Movement Disorders Clinical Practice@MDCP_Journal·Feb 9

Stimulants in cerebellar ataxia? 🧠 In this patient‑reported study, alertness (95%), fatigue (90%), and executive function (80%) all improved with stimulant therapy—supported by a 26% improvement in PROM‑Ataxia Mental scores. When evaluating cerebellar disorders, screen for fatigue, mental fog, and CCAS features—these may be modifiable and have meaningful QoL impact! @SchmahmannLab movementdisorders.onlinelibr…

Schmahmann Lab avatar
Schmahmann Lab@SchmahmannLab·Jan 12

Implication: enhancing emotional support and camaraderie is likely to improve quality of life in patients with ataxia. Kudos to @AmarDhand for developing PERSNET, our RA-now medical student James Concepćion for leading the study, Broadstreet for statistical analysis. @NAF_Ataxia

Schmahmann Lab avatar
Schmahmann Lab@SchmahmannLab·Jan 12

rdcu.be/eYCXg We examined personal social network metrics in patients with ataxia. Positive relationships, camaraderie, weekly communication, and high levels of emotional support correlate with higher quality of life and better physical function.

Schmahmann Lab avatar
Schmahmann Lab@SchmahmannLab·27 Nov 2025

CALL TO ACTION: @US_FDA and @DrMakaryFDA need to hear the outrage from @ataxia patients and families about their blocking of the safe drug troriluzole that slows progression in SCA. @naf can share this response. Email your thoughts now to NAF ataxia.org

Schmahmann Lab avatar
Schmahmann Lab@SchmahmannLab·7 Nov 2025

Gil was a fabulous friend, colleague and co-author. His epidemiological statistical acumen was deeply impressive as was his commitment to @NAF_Ataxia patients and clinician researchers. We miss him deeply already. The journey continues in his honor.

NAF is saddened by the passing of Dr. Gilbert L’Italien on November 1. Dr. L’Italien was a devoted researcher who advanced programs to develop treatments for Ataxia across several pharmaceutical companies. (1/2)

Post attachment
Schmahmann Lab avatar
Schmahmann Lab@SchmahmannLab·5 Nov 2025

Senate is paying attention. FDA sunk Biohaven’s troriluzole yesterday, despite the fact that it slows progression compared to the natural history studies in the US and Europe, according to rigorous statistical analysis of real world evidence. aging.senate.gov/press-relea…

Schmahmann Lab avatar
Schmahmann Lab@SchmahmannLab·4 Nov 2025

This is the letter the @WSJ just refused to publish because they did not “have space”. Another snub to @NAF_Ataxia patients and their needs, compounding their distress and the disgrace that is the @FDA @DrMakaryFDA

Post attachment